S. Alekar

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Phase II Trial of the Anti-CD 19 Bispecific T Cell – Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

H. Einsele, G. Zugmaier, H. Horst, 2014 .

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

G. Zugmaier, H. Horst, R. Bargou, 2014, Blood Cancer Journal.

ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS

T. Cloughesy, D. Reardon, A. Lassman, 2017 .

Adverse Events in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): A Literature Review of Recent Clinical Trials

E. Chang, M. Kelsh, A. Stein, 2016 .

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Albrecht Reichle, Hermann Einsele, Monika Brüggemann, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

D. Xuan, M. Maitland, A. Tolcher, 2021, Clinical Cancer Research.

Bispecific Antibodies in the Treatment of Hematologic Malignancies

P. Lammers, S. Gill, I. Jacobs, 2019, Clinical pharmacology and therapeutics.

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

T. Cloughesy, D. Reardon, A. Lassman, 2020, Investigational New Drugs.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.